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The death rate of people who have a chronic disease is lower among former smokers than current smokers. State 
tobacco cessation quitlines are available for free in every state. The objective of our study was to compare demographic 
characteristics, use of quitline services, and quit rates among a sample of quitline callers.
Methods 
We used data from 15 states on tobacco users aged 18 or older who enrolled with a quitline between October 1, 2005, 
and May 31, 2008; 9 states also provided data from 7-month follow-up surveys. We used descriptive statistics and 
logistic regression to compare callers by disease status.
Results 
Among 195,057 callers, 32.3% reported having 1 or more of the following chronic diseases: 17.7%, asthma; 5.9%, 
coronary artery disease; 11.1%, chronic obstructive pulmonary disease; and 9.3%, diabetes; 9.0% had 2 or more chronic 
diseases. Callers who had a chronic disease were older and better educated; more likely to be female, have Medicaid or 
other health insurance, and have used tobacco for 20 years or more; and less likely to quit smoking (22.3%) at 7 
months than callers who had none of these chronic diseases (29.7%).
Conclusion 
About one-third of tobacco users who call state quitlines have a chronic disease, and those who have a chronic disease 
are less likely to quit using tobacco. Continued efforts are needed to ensure cessation treatments are reaching tobacco 
users who have a chronic disease and to develop and test ways to increase quit rates among them.
Introduction
Each year cigarette smoking causes 443,000 deaths and $193 billion in health care expenditures and productivity 
losses in the United States (1,2). These costs are higher among people who have a chronic disease such as diabetes, 
cancer, or cardiovascular disease. In 2006, the age-adjusted prevalence of smoking was 36.9% among people who had 
a smoking-related chronic disease and 19.3% among those who had other chronic diseases or had no chronic disease 
(3,4). Smoking is an independent and modifiable risk factor for type 2 diabetes (5), heart disease (6), and chronic 
obstructive pulmonary disease (COPD) (7). An estimated 90% of deaths from COPD are directly attributable to 
smoking; quitting is the only proven way to stop progression of the disease (7). Smoking has also been shown to 
increase the onset and severity of asthma and heart disease (6,8). One cost-effective population-based strategy to 
increase smoking cessation is proactive telephone counseling (9–12). In the United States, a toll-free national number 
(1-800 QUITNOW) connects callers to their state quitline for services such as mailed materials, proactive counseling, 
and mailed nicotine replacement therapy (NRT) (patch or gum). Quitlines provide a brief, minimally invasive, 
convenient form of cessation treatment, reach diverse segments of the population, and may be especially useful for 
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chronically ill people who have limited mobility (9). The option of receiving services over the telephone increases the 
use of cessation treatments (13).
Little is known about the use of quitlines and quit rates among tobacco users who have a chronic disease. A few studies 
have described the characteristics of people who use quitlines but did not describe the prevalence of chronic disease 
among their study populations (14). The objective of our study was to compare the characteristics, use of quitline 
services, and quit rates among a sample of quitline callers. This information will provide an understanding of how state 
quitlines are serving tobacco users who have a chronic disease and help to determine whether treatment should be 
modified for this population.
Methods
Alere Wellbeing conducted this observational study. Alere is the largest provider of quitline services in the United 
States, serving more than 350,000 tobacco users annually. This study was approved by the Western Internal Review 
Board.
Sample
Fifteen state quitlines operated by Alere at the time of the study (Alaska, Connecticut, Georgia, Hawaii, Indiana, 
Maryland, Missouri, North Carolina, Oklahoma, Oregon, South Carolina, Utah, Virginia, Washington, and Wisconsin) 
agreed to participate and allowed use of data routinely collected from quitline callers. We included data if the caller 
was a current tobacco user, was aged 18 or older, and had enrolled in a state quitline between October 1, 2005, and 
May 31, 2008. We selected this period so that we could include data from 7-month follow-up telephone surveys. We 
excluded data on callers who were pregnant or did not have a reliable telephone number. The final sample included 
195,057 callers. The standard cessation benefits offered to all callers, regardless of readiness to quit, were a single 
“reactive” counseling call and mailed materials. For callers ready to quit within 30 days (and only these callers), the 
quitline offered a multicall program, consisting of the standard reactive counseling call plus 3 or 4 proactive counseling 
calls and NRT. Of the 195,057 callers, 128,997 (66.1%) were enrolled in the multicall program. All but 2 states (North 
Carolina and Virginia) provided free NRT (2 or 4 weeks) for selected populations (eg, uninsured callers). State services 
varied according to funding available for tobacco control programs (15).
Nine state quitlines also provided data from telephone surveys conducted 7 months after enrollment with randomly 
selected callers. These follow-up surveys were conducted by an external evaluation service between April 1, 2006, and 
December 31, 2008. Response rates ranged from 34% to 52%, and 4,730 callers completed the survey; 68.7% (n = 
3,250) were enrolled in the multicall program. Callers provided verbal consent before administration of the survey.
Measures
Quitlines routinely collect information from callers on demographics and tobacco use, quitline services used (whether 
counseling only or counseling and NRT and number of counseling calls completed), and quit outcomes. For this study, 
we used data on caller demographics (age, sex, race/ethnicity, education, and insurance status), current tobacco use, 
tobacco type used (cigarettes vs other), years of tobacco use (<20 years vs ≥20 years), amount used (eg, cigarettes per 
day), time to first tobacco use after waking (a brief measure of addiction [16]), whether they live with or work with 
smokers, and how they heard about the quitline. To assess whether a caller had a chronic disease, quitline telephone 
staff asked, “Have you been diagnosed with any of the following conditions: asthma, chronic obstructive pulmonary 
disease or emphysema, coronary artery disease (CAD), or diabetes?” The 7-month follow-up survey asked about use of 
NRT since enrolling with the quitline and last use of tobacco since enrolling (≥7 days and ≥30 days). These measures 
have been used in other quitline studies (17).
Analyses
We used frequencies and means to describe demographic characteristics and χ  tests or analysis of variance to compare 
demographics, the types of quitline services used, and abstinence by chronic disease status (any chronic disease vs 
none of the 4 diseases) and for each disease separately (eg, asthma only vs no asthma). We defined “any chronic 
disease” as having 1 disease or a combination of diseases. We also compared the demographic characteristics of the 
entire sample of callers with the callers who participated in the 7-month telephone survey.
Using complete case analyses of the 7-month survey data (n = 4,730), we conducted multiple logistic regression to 
determine whether chronic disease was associated with 30-day abstinence. We repeated these analyses for 7-day 
abstinence. To inform our selection of covariates to be included in regression models, we performed correlation 
analyses to determine colinearity of independent variables. As expected, age was correlated with years of tobacco use (r 
= 0.85); time to first tobacco use after waking was correlated with cigarettes per day (r = 0.41); and race was correlated 
with ethnicity (r = 0.37). Because age was more strongly associated with abstinence than years of tobacco use, we used 
age in the logistic regression models. We included all of the covariates in the initial regression model and then used 
backwards elimination to remove variables that were not significant (P ≥ .05). The final model included chronic 
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disease status (variable of interest), age, sex, race, education, insurance status, number of cigarettes smoked per day, 
and state (entered to control for state variability in treatment offerings). The final model used chronic disease as a 2-
level predictor (any of the 4 diseases vs no disease) and then as a 6-level variable (asthma only, CAD only, COPD only, 
diabetes only, ≥2 diseases, or no disease). We repeated this analysis with callers in the multicall program (n = 3,250) 
and added number of counseling calls completed and receipt of NRT to determine the association between chronic 
disease and abstinence after controlling for these factors. Analyses were conducted in SAS version 9.1.3 (SAS Institute, 
Cary, North Carolina).
Results
Among 195,057 tobacco users who enrolled with 1 of the 15 state quitlines between October 1, 2005, and May 31, 2008, 
32.3% reported having at least 1 of the 4 chronic diseases; 17.7% had asthma (11.2%, asthma only), 5.9%, CAD (2.4%, 
CAD only); 11.1% COPD (4.8%, COPD only); and 9.3%, diabetes (4.9% diabetes only). These proportions include some 
duplication; 17,609 callers (9.0%) had 2 or more chronic diseases; 132,033 (67.7%) had none of the 4 diseases, and 
45,415 (23.3%) had only 1 chronic disease. Among the 9.0% who had 2 or more chronic diseases, 66.5% had asthma.
In bivariate analyses, callers who had any chronic disease differed significantly from callers who had none (Table 1) by 
age, sex, education, insurance status, how long they used tobacco, exposure to smokers at home or work, time to first 
tobacco use after waking, and how they heard about the quitline. Callers also differed significantly by type of chronic 
disease. For example, compared with callers in the other 3 single disease groups, callers who had asthma only were 
younger, callers who had COPD only were more likely to be non-Hispanic white, and callers who had COPD only or 2 
or more chronic diseases were more likely to use tobacco within 5 minutes of waking. The callers who participated in 
the 7-month follow-up survey had similar characteristics.
The mean number of calls completed among callers in the multicall program ranged from 2.4 calls to 2.9 calls and 
differed significantly between disease groups (any vs none, asthma only vs no asthma, etc.). Similarly, the percentage 
of callers in the multicall program who received NRT ranged from 54.6% to 69.8% and differed significantly between 
disease groups.
In unadjusted analyses of 7-day and 30-day quit rates, callers who had any chronic disease were less likely to quit 
tobacco than callers who had none of these chronic diseases (Figure). The 30-day quit rate was 22.3% among callers 
who had any chronic disease and 29.7% among callers who had none of these diseases. Quit rates also differed 
significantly between callers who had none of these chronic diseases and callers in each of the 4 disease groups (P 
< .001) and callers who had 2 or more chronic diseases (P < .001).
Figure. Unadjusted quit rates by chronic disease status among the 4,730 callers who completed the 7-month survey; 
68.7% of survey completers were enrolled in the multicall program. Error bars represent 95% confidence intervals. 
Abbreviations: CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease. [A tabular version of this 
figure is also available.]
In multivariate analyses of 30-day quit rates among respondents to the 7-month follow-up survey, callers who had any 
chronic disease were less likely to quit than callers who had no chronic disease. African American callers, callers who 
had Medicaid insurance, and callers who smoked more cigarettes per day were each less likely to quit. Callers who had 
more than a high school education and callers who completed more calls were more likely to quit. We found similar 
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results among 7-month survey respondents who were enrolled in the multicall program (Table 2). In a comparison of 
callers who had no disease and callers who had only 1 disease (eg, asthma only) or 2 or more diseases, having a chronic 
disease was associated with lower quit rates (Wald χ 5 = 20.3, P = .001), even after controlling for covariates and state 
(Table 3). We found similar results in analyses of 7-day quit rates.
Discussion
This study contributes to the limited data available on the use of state tobacco quitlines and quit rates among people 
who have chronic diseases. In our study, one-third of tobacco users enrolled in 15 state quitlines had at least 1 of 4 
selected chronic diseases. Although we found that callers who had a chronic disease were less likely to quit tobacco 
than callers who had none of the 4 diseases, another study reported higher quit rates among people who had smoking-
related diseases (18). Smokers in that study, however, were not receiving cessation treatment. The quit rates found in 
our study (19.7%–29.7%) are within the range (16%–36%) observed in other state quitlines (9,19). The 30-day quit 
rates among callers who had diabetes (21.6%) and COPD (19.7%) in our study are higher than rates found in studies of 
primary-care–based smoking cessation interventions: 17% among smokers who had diabetes (20) and 16% among 
smokers who had COPD (21). Demographic differences by chronic disease status (eg, older age, more years of 
smoking) could explain some of the variability in quit rates.
Although quitline callers who had any chronic disease were more likely to use tobacco within 5 minutes of waking (ie, 
they had a greater level of nicotine addiction) than callers who had no disease, they were less likely to receive NRT, 
even though none of the selected diseases contraindicates NRT. The Public Health Service Clinical Practice Guideline 
states that NRT should be used with caution by those in the immediate postmyocardial infarction period, those who 
have serious arrhythmias, and those who have unstable angina pectoris (9). The Centers for Disease Control and 
Prevention (CDC) recommends that quitlines be funded to provide 8 weeks of NRT to people who have Medicaid or no 
health insurance and 2 weeks to others (22). Research is needed to determine whether tobacco users who have a 
chronic disease are less likely than tobacco users with none of these diseases to receive NRT through quitlines because 
of state eligibility requirements, caller refusal, or other factors, such as medical advice.
Although two-thirds of callers in this study had enrolled in the multicall counseling program, they completed on 
average only 2 or 3 counseling calls, which is consistent with the general quitline population (23). In addition, although 
we found that quit rates increased as the number of completed calls increased, we found that callers who had a chronic 
disease completed more calls than callers who had no disease, but they had lower quit rates. These findings are 
inconsistent with research showing that abstinence increases with treatment intensity (9,24,25). In our study, 
however, statistical significance could have resulted from the large sample size; the number of calls completed differed 
by less than 1 call (0.3 to 0.4 calls) among groups. Further research is needed to examine this apparent discrepancy.
In summary, we observed differences in characteristics of quitline callers according to chronic disease. Callers who had 
asthma only were younger, callers who had COPD only were more likely to be non-Hispanic white, and callers who had 
COPD only or 2 or more chronic diseases were more likely to use tobacco within 5 minutes of waking. These and other 
differences suggest future efforts are needed to improve use and effectiveness of treatment in these populations.
This study had several limitations. First, we studied only 4 chronic diseases; we selected these 4 because they are 
routinely asked about during quitline enrollment. Tobacco users who have any of these 4 diseases are considered to 
have greater health risks than nonsmokers (6).
Second, we relied on self-reported disease status, which may have resulted in under- or overreporting (eg, some people 
may mistake their smoking-induced respiratory symptoms for symptoms of asthma). However, studies show that self-
report adequately represents disease status for epidemiological purposes (26). Self-reported smoking status could also 
have been subject to bias, but studies show that self-reported abstinence adequately describes population-level 
smoking rates (27). Third, we pooled follow-up data among different sampling frames from 9 states. We were not able 
to calculate follow-up survey response rates or intent-to-treat quit rates because we did not have access to the 
denominators (ie, the number sampled for the segment of follow-up that overlapped with our study timeline). In 
general, survey response rates reported by these quitlines range from 34% to 52%. Fourth, quitlines offered different 
levels of services during the study, and this variable might have influenced enrollment and outcomes. Offering free 
NRT via state quitlines can increase the number of calls to the quitline, reach larger proportions of certain populations 
(28,29), and improve outcomes (30,31). By adding state to the multivariate analyses, we attempted to control for the 
difference among states in quitline services. Finally, using different criteria for selecting variables to include in 
statistical models (eg, P values > .05) may have produced additional covariates for modeling.
Despite these limitations, this study offers new information about the relationship between chronic disease and 
quitline services and points out the need to integrate cessation treatment into the medical management of chronic 
diseases (22,32–34). Smokers who have a smoking-related chronic disease and quit have a lower risk for death from 
the disease than those who continue to smoke (7). Quitlines are an effective population-based cessation intervention 
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that are available for free in all states and can be easily integrated into chronic disease programs by encouraging 
referrals to quitlines when tobacco users are identified in screening and preventive care programs (22). In a recent 
survey of quitlines, all but 2 of the 21 states responding noted their quitline had worked with chronic disease programs 
to add tobacco treatment (19). For example, in 2010, the CDC’s breast, cervical, and colorectal cancer screening 
programs began screening for tobacco use; for people who expressed an interest in quitting, the programs made 
referrals to community-based cessation programs, including quitlines. Coordinated tobacco control efforts have been 
shown to increase awareness of quitlines by chronic disease staff and increase the number of fax referrals to quitlines 
(35). The PHS Clinical Practice Guideline recommends that clinicians identify smokers, provide brief counseling, and 
make referrals to cessation services and that health care systems facilitate patient access to quitlines and promote their 
use (9). Resources are needed for state quitlines to ensure that comprehensive, proactive counseling and NRT are 
available to all tobacco users who seek assistance with quitting.
The findings of this study also indicate quitlines may need to offer more intensive treatment for callers who have a 
chronic disease than for callers who do not have a chronic disease. Such treatment may include re-enrollment, longer 
duration of NRT, and combination therapy (nicotine patch and gum). Research indicates that intensive or combined 
pharmacological treatments are more cost-effective when delivered to high-risk populations (36).
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Table 1. Characteristics of Quitline Users (N = 195,057) by Chronic Disease 
























9,482 (4.9) 17,609 (9.0)






48.6 (12.4) 51.0 (11.6)
Age group, y
18–24 8.8 15.9 21.0 1.4 1.4 3.6 2.4
25–44 33.6 48.4 51.7 18.0 19.7 31.3 23.6
45–64 48.8 32.3 25.6 63.2 64.1 55.4 62.3
≥65 8.8 3.4 1.7 17.4 14.8 9.7 11.7
Sex
Female 67.1 57.1 71.0 49.3 64.5 60.1 72.0
Race/ethnicity
White non-Hispanic 76.6 76.2 74.3 78.6 86.0 65.9 79.6
African American non-
Hispanic
13.2 13.6 13.6 13.7 7.4 22.9 10.7
Native American or 
Alaska Native non-
Hispanic
5.2 3.8 5.4 4.6 4.4 4.9 6.0
Asian non-Hispanic 0.7 1.2 0.9 0.4 0.2 1.2 0.5
Hispanic 4.2 5.2 5.9 2.8 2.0 5.1 3.3
Education
≤High school 60.6 56.7 60.8 59.3 62.9 56.4 61.7
Insurance status
Insured 42.3 43.0 34.2 55.0 46.6 49.2 43.0
Medicaid 28.3 15.8 27.0 20.3 25.8 24.2 35.6
Uninsured 29.4 41.6 38.8 24.8 27.6 26.7 21.4
Exposure to smokers
Smokers at home 39.6 30.5 38.7 36.3 39.5 35.1 44.0
Smokers at work 9.8 18.2 13.0 10.0 8.4 12.1 5.6
Smokers at home and 
work
11.8 18.7 17.8 10.2 8.7 10.8 7.3
a a b

















Used ≥20 y 74.6 54.3 48.6 92.1 92.5 80.8 89.6
First use within 5 min of 
waking
56.7 47.7 54.4 52.8 60.1 51.8 61.7
No. of cigarettes per day, 
mean (SD)






21.2 (13.3) 23.4 (14.8)
How caller heard of quitline
Health care professional 17.7 10.9 14.7 20.3 17.5 17.5 21.1
Family or friend 18.8 22.0 21.8 15.9 18.1 17.2 16.9
Radio or television 26.4 32.4 28.4 25.8 26.5 28.9 22.7
Other 37.1 34.7 35.1 38.0 37.9 36.5 39.3
Enrollment type
In multicall counseling 
program
66.3 66.0 66.9 63.6 67.2 64.9 66.8
Services used by callers enrolled in the multicall counseling program (n = 128,997)
No. of calls completed, 
mean (SD)




2.7 (1.9) 2.9 (1.9)
Mailed nicotine 
replacement therapy
63.7 69.8 68.6 54.6 65.6 62.1 59.6
Abbreviations: CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease. 
 In bivariate comparisons of “any chronic disease” group and the “no disease group,” all differences were significant at P 
< .001. The survey asked about the following 4 chronic diseases only: asthma, CAD, COPD, and diabetes. All values are 
percentages unless noted. 
 In 6-level comparisons (the “no disease” group, asthma only, CAD only, COPD only, diabetes only, and ≥2 chronic 
disease), all differences were significant at P < .001.
 
Table 2. Comparison of “Any Chronic Disease” and “No Disease Groups” for 
30-Day Quit Rates Among Callers Who Participated in 7-Month Follow-Up 
Survey and Multicall Counseling Program (n = 3,250)
Effect Odds Ratio (95% CI) P Value
Any chronic disease 0.81 (0.68–0.96) .02
No chronic disease 1 [Reference]
Race
African American 0.73 (0.58–0.91) .04
Other 0.89 (0.67–1.91) .74
White 1 [Reference]
Insurance status
Medicaid 0.69 (0.54–0.88) .003
Uninsured 0.93 (0.76–1.15) .23
Other insurance 1 [Reference]
Education
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Effect Odds Ratio (95% CI) P Value
≥High school 1 [Reference]
Nicotine replacement therapy (patch or gum)
Used 0.93 (0.70–1.24) .61
Did not use 1 [Reference]
Other
No. of cigarettes per day 0.98 (0.98–0.99) <.001
No. of calls completed 1.05 (1.02–1.09) .003
Abbreviation: CI, confidence interval. 
 The survey asked about the following 4 chronic diseases only: asthma, CAD, COPD, and diabetes. Adjusted logistic 
regression model included all variables in the table, plus age, sex, and state. 
 Each race category includes Hispanics and non-Hispanics. 
 Odds ratios represent coefficients for these continuous variables.
 
Table 3. Comparison of 6 Disease Groups for 30-Day Quit Rates Among 
Callers Who Participated in 7-Month Follow-Up Survey and Multicall 
Counseling Program (n = 3,250)
Effect Odds Ratio (95% CI) P Value
Disease group
Asthma only 0.84 (0.65–1.10) .91
CAD only 0.86 (0.50–1.48) .88
COPD only 0.71 (0.48–1.06) .37
Diabetes only 0.79 (0.55–1.13) .75
≥2 diseases 0.81 (0.61–1.07) .81
No chronic disease 1 [Reference]
Race
African American 0.72 (0.57–0 .91) .03
Other 0.90 (0.67–1.20) .71
White 1 [Reference]
Insurance status
Medicaid 0.69 (0.54–0.88) .003
Uninsured .93 (0.76–1.15) .23
Other insurance 1 [Reference]
Education
>High school 1.22 (1.04–1.44) .02
≥High school 1 [Reference]
Nicotine replacement therapy (patch or gum)
Used 0.93 (0.70–1.24) .61
Did not use 1 [Reference]
Other
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Effect Odds Ratio (95% CI) P Value
No. of calls completed 1.06 (1.02–1.09) .004
Abbreviation: CI, confidence interval; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease. 
 Having a chronic disease was associated with lower quit rates, even after controlling for covariates and state (Wald χ 5 = 
20.3, P = .001). The survey asked about the following 4 chronic diseases only: asthma, CAD, COPD, and diabetes. Logistic 
regression model included all variables above plus age and sex, which were not significant, and state.  
 Each race category includes Hispanics and non-Hispanics. 
 Odds ratios represent coefficients for these continuous variables.
 
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. 
Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, 
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